Dark

Check out our Dark Pool Levels

GBS
GBS Inc. Common Stock
stock NASDAQ

Inactive

Oct 26, 2022

0.4732USD-0.042%(-0.0002)11,030

Pre-market

0.00USD-100.000%(-0.47)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 8, 2022

03:11AM EST GBS: Spit it Out: Testing Without the Blood Benzinga

Dec 20, 2021

07:25AM EST The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET). RTTNews

07:10AM EST GBS Inc. to Participate in the Upcoming January Virtual Investor GlobeNewswire Inc

Dec 13, 2021

08:03AM EST GBS Inc. Announces Application For FDA Breakthrough Device Designation To Fast Track Rapid Saliva Glucose Test Benzinga

08:00AM EST GBS Inc. Announces Application for FDA Breakthrough Device GlobeNewswire Inc

Nov 30, 2021

04:45PM EST GBS Inc. Announces Plans For Clinical SARS-CoV-2 Antibody Trials Following Validation Study Benzinga

08:00AM EST GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study. GlobeNewswire Inc

Nov 11, 2021

04:17PM EST GBS Q1 EPS $(0.10) Up From $(0.27) YoY Benzinga

04:06PM EST Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test GlobeNewswire Inc

03:55AM EST Earnings Scheduled For November 11, 2021 Benzinga

Nov 1, 2021

04:05PM EDT GBS Inc. to Present First Quarter 2022 Financial Results and GlobeNewswire Inc

08:16AM EDT GBS Inc. Appoints Professor Steven Boyages, PhD, The Chairman Of The Board, To The Position Of Interim Chief Executive Officer Benzinga

08:00AM EDT GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced changes to its executive leadership team as the Company advances into a new phase focused on product development and planned manufacturing. GlobeNewswire Inc

Oct 19, 2021

05:38AM EDT GBS Shares Spike Higher Premarket After Licensor for Glucose Salivary Test iQ Group Global Announced GBS Filed Pre-Submission Package with FDA Benzinga

05:16AM EDT iQ Group Global Announced its Licensee GBS has Filed a Pre-Submission Package with the FDA for the Real-Time Glucose Salivary Test Benzinga

Oct 13, 2021

01:38PM EDT GBS Reports Pre-Submission Package Is With The FDA Benzinga

08:30AM EDT GBS Inc. Announces its Pre-Submission package is with the FDA GlobeNewswire Inc

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 7, 2021

04:05PM EDT GBS Inc. to Present at Upcoming September GlobeNewswire Inc

Sep 1, 2021

05:59AM EDT GBS Shares Spike Higher Premarket; Co Markets Saliva Test for Diabetes Management and Previously Announced Collaboration on Covid-19 Diagnostic With Harvard's Wyss Institute Benzinga

Aug 18, 2021

10:02AM EDT Point of Care Testing Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing Benzinga

Aug 17, 2021

12:05PM EDT Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing Benzinga

Aug 11, 2021

04:30PM EDT GBS FY21 EPS $(0.68) vs $(0.37) In FY20 Benzinga

04:05PM EDT - Awarded $4.7 Million Government Grant Funding to support the building of ahigh-tech manufacturing facility - GlobeNewswire Inc

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Jul 29, 2021

08:30AM EDT GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial GlobeNewswire Inc

Jul 26, 2021

08:00AM EDT GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced L.E.K. Consulting Hong Kong Pty Limited (L.E.K. Consulting) will be aiming to deliver and engage within two months a shortlist of suitable commercial partners for distribution in China. GlobeNewswire Inc

Jul 8, 2021

02:48PM EDT Mid-Afternoon Market Update: Dow Falls 1%; Digital Brands Shares Jump Benzinga

12:16PM EDT Mid-Day Market Update: Nasdaq Tumbles 200 Points; GBS Shares Spike Higher Benzinga

09:53AM EDT Shares of GBS Inc. (GBS) are skyrocketing over 40% Thursday morning, after the life sciences company announced that it has been awarded a US$4.7 million, Australian Federal Government scientific grant to fund the build out of a Biosensor manufacturing facility. RTTNews

09:23AM EDT GBS Says Awarded $4.7M Australian Federal Government Science Grant To Manufacture Biosensor Technology Benzinga

09:22AM EDT GBS Awarded $4.7 Million Australian Federal Government Science GlobeNewswire Inc

Jun 8, 2021

08:11AM EDT GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced survey results from more than 300 patients globally as part of its development and go-to-market strategy. GlobeNewswire Inc

May 14, 2021

08:38AM EDT GBS Q1 EPS $(0.27) Down From $(0.01) YoY Benzinga

08:30AM EDT - Anticipate Emergency Use Submission for SARS-CoV-2Antibody Biosensor Test in the Second Half of 2021- GlobeNewswire Inc

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 15, 2021

12:00PM EDT GBS, Inc. Receives Approval To Commence Validation Clinical Study For Rapid SARS-CoV-2 Diagnostic Test Benzinga

11:29AM EDT GBS, Inc. Receives Approval to Commence Validation Clinical Study GlobeNewswire Inc

Feb 18, 2021

08:54AM EST GBS Inc. Enters Sponsored Research Agreement With Johns Hopkins Bloomberg School Of Public Health To Accelerate Development Of Saliva-Based Diagnostic Tests Benzinga

08:54AM EST GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generationsaliva-baseddiagnostic tests. GlobeNewswire Inc

Feb 16, 2021

08:17AM EST GBS Q4 EPS $(0.23) Down From $(0.22) YoY, Sales $283.00K Benzinga

08:00AM EST - December 2020 Initial Public Offering generated $21.6m in gross proceeds andlisting on the NASDAQ Stock Market GlobeNewswire Inc

Jan 21, 2021

06:10AM EST GBS Inc Files For Offering Of Up To 3M Shares Issuable Upon Conversions Of Series B Convertible Preferred Stock By Selling Stockholders Benzinga

Dec 28, 2020

05:13PM EST GBS, Inc. Announces Closing of Upsized $21.6 Million Initial GlobeNewswire Inc

Dec 23, 2020

12:28PM EST GBS Inc. Shares Open For Trade At $9.24; IPO Priced At $17/Share Benzinga

10:49AM EST UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial GlobeNewswire Inc

09:12AM EST GBS Inc. Shares Will Open For Quote At 12:15 p.m. EST, Expected To Open For Trade After 12:25 a.m. EST; IPO Priced At $17/Share Benzinga

Dec 22, 2020

10:17PM EST GBS Inc. Announces Pricing of Initial Public Offering GlobeNewswire Inc

Share